Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

208
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
208
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

1
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
1
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

1
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
1
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

204
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
204
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

189
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
189
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

582
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
582

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison in the Use of Regulatory Pathways Between Health Canada and the Food and Drug Administration: A Cross-sectional Study.

Journal of general internal medicine·2026
Same author

The World Expected More of Canada: Canada and the Pandemic Agreement.

International journal of social determinants of health and health services·2026
Same author

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.

BMJ open·2026
Same author

Evaluating conflict-of-interest governance among Canadian medical societies using a novel assessment tool: A cross-sectional study.

PloS one·2026
Same author

Orphan Drug Approval in Canada, 1999-2022: A Cross-sectional Study.

International journal of health policy and management·2026
Same author

Are gaps in the time of submissions and approvals of new drugs between Health Canada and the Food and Drug Administration related to therapeutic value? A cross-sectional study.

Health policy (Amsterdam, Netherlands)·2026

Related Experiment Video

Updated: Feb 13, 2026

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
14:14

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups

Published on: May 13, 2022

6.4K

Combating corruption in the pharmaceutical arena.

Joel Lexchin1, Jillian Clare Kohler2, Marc André Gagnon3

  • 1Professor Emeritus, School of Health Policy and Management, Faculty of Health, York University, Toronto, Canada., jlexchin@yorku.ca.

Indian Journal of Medical Ethics
|March 19, 2018
PubMed
Summary
This summary is machine-generated.

This study examines corruption in the pharmaceutical industry, focusing on legislative, financial, ethical, and communication issues. It proposes structural solutions to align incentives with social outcomes and reduce conflicts of interest.

More Related Videos

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
07:00

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

Published on: August 11, 2017

8.7K
Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
07:45

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

4.0K

Related Experiment Videos

Last Updated: Feb 13, 2026

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
14:14

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups

Published on: May 13, 2022

6.4K
Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
07:00

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

Published on: August 11, 2017

8.7K
Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
07:45

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

4.0K

Area of Science:

  • Pharmaceutical industry ethics
  • Healthcare policy and regulation
  • Medical research integrity

Background:

  • Recent reports highlight widespread corruption in healthcare, particularly within the pharmaceutical sector.
  • Corruption impacts drug discovery, development, distribution, and clinical use.
  • Key areas include legislative/regulatory, financial, ethical, and communication facets of the industry.

Purpose of the Study:

  • To analyze structural issues contributing to corruption in the pharmaceutical arena.
  • To identify and consider solutions for legislative, financial, ethical, and communication-related corruption.
  • To propose reforms aligning financial incentives with public health goals and minimizing conflicts of interest.

Main Methods:

  • Analysis of structural considerations in pharmaceutical lifecycle (discovery to clinical use).
  • Examination of specific issues: user fees, intellectual property rights, commercial sponsorship, research funding linkage, payment transparency, and regulatory sanctions.
  • Focus on incentive structures for all stakeholders in the pharmaceutical system.

Main Results:

  • Identified corruption in legislative/regulatory, financial, ideological/ethical, and communication domains.
  • Highlighted issues with user fees, intellectual property, ghostwriting, research funding, payment transparency, and regulatory enforcement.
  • Emphasized the need for incentive alignment and conflict of interest mitigation.

Conclusions:

  • Structural reforms are crucial to combat pharmaceutical corruption.
  • Aligning financial incentives with social outcomes is essential for ethical pharmaceutical practices.
  • Minimizing conflicts of interest among researchers and clinicians is a key objective for improving healthcare integrity.